Drugs / Pracytarabine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07300488 | Sep 2025 → Feb 2027 expected | hepatocellular carcinoma | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pracytarabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300488 ↗ |
| Route | Intravenous | “administered as a continuous intravenous infusion” NCT07300488 ↗ |